High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3

(2011) S. S. Lee et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Peginterferon Alfa-2a Is Superior to Peginterferon Alfa-2b in the Treatment of Naïve Patients with Hepatitis C Virus Infection: Meta-Analysis of Randomized Controlled Trials

(2011) Ashwani K. Singal et al.   DIGESTIVE DISEASES AND SCIENCES

Treatment of chronic hepatitis C genotype 1 patients at an academic center in europe involved in prospective, controlled trials: Is there a selection bias?

(2011) Sandra Beinhardt et al.   HEPATOLOGY

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2011)   JOURNAL OF HEPATOLOGY

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

(2011) Kenneth E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers

(2011) Sanjeev Arora et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study

(2010) Andri Rauch et al.   GASTROENTEROLOGY

Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States

(2010) Maria Stepanova et al.   HEPATOLOGY

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin

(2010) Thomas-Matthias Scherzer et al.   JOURNAL OF HEPATOLOGY

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

(2010) Michael W. Fried et al.   JOURNAL OF HEPATOLOGY

Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response

(2009) Peter Ferenci et al.   GASTROENTEROLOGY

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C

(2009) Avidan U. Neumann et al.   JOURNAL OF HEPATOLOGY

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C

(2009) Maribel Rodriguez-Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C

(2008) Sarah Maylin et al.   GASTROENTEROLOGY

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

(2008) Ming-Lung Yu et al.   HEPATOLOGY

Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

(2008) Martin Lagging et al.   HEPATOLOGY

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY